Toru Nakai
Profile
Performance in office
Tenure
Tenure
Background
He joined Nippon Shinyaku in April 1995 and became General Manager of Business Planning in April 2016. He joined the board in June 2019 and became Representative Director and President in June 2021. It was five years from General Manager of Business Planning to President, and 26 years from joining.
Selection
In June 2021 he became Representative Director and President, succeeding Shigenobu Maekawa. The promotion came two years after he joined the board. In the fiscal year ended March 2021, the year before he took office, consolidated net sales were ¥121.9 billion and operating income ¥27.2 billion, up from ¥116.6 billion and ¥21.7 billion the year before.
Initiatives
He took over from his predecessor Shigenobu Maekawa and pushed ahead with in-house US sales of the antisense oligonucleotide drug Viltepso. Consolidated net sales grew from ¥121.9 billion in the year before he took office to ¥170.8 billion in the fiscal year ended March 2026, and operating income from ¥27.2 billion to ¥35.5 billion. In April 2022 the company moved to the Prime Market under the Tokyo Stock Exchange's market restructuring.
Career
Career
Nippon Shinyaku
| Date | Position |
|---|---|
| Apr 1995 | Joined |
| Apr 2016 | General Manager, Business Planning Department |
| Jun 2019 | Director |
| Jun 2021 | Representative Director, President |
References 1
References (Japanese primary sources)
- 日本新薬 有価証券報告書【役員の状況】